Print this page
-
An Open-Label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Protocol: 052011Principal Investigator:
- Missak Haigentz MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Breast
Esophagus
Lung -
PERitoneal Carcinomatosis LEveraging ctDNA guided treatment Study in GI Cancer (PERICLES Study).
Protocol: 072013Principal Investigator:
- Henry Richard Alexander M.D (Rutgers University)
Applicable Disease Sites: Unknown Sites
Ill-Defined Sites
Colon
Esophagus
Stomach
Rectum
Pancreas
Other Digestive Organ
Small Intestine -
A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations.
Protocol: 022004Principal Investigator:
- Neil Palmisiano MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Leukemia, other -
A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Cancers of the Stomach, Breast, Lung and Cervix.
Protocol: 192004Principal Investigator:
- Christian Hinrichs (Rutgers University)
Applicable Disease Sites: Any Site
Stomach
Breast
Lung
Cervix -
A Phase 2 Study of Blinatumomab in Combination with Nivolumab, a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged < 1 to < 31 Years Old with First Relapse.
Protocol: 112011Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Any Site -
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies.
Protocol: 072014Principal Investigator:
- Seth Cohen MD (Monmouth Medical Center)
Applicable Disease Sites: Any Site